Table 3 Demography, systemic, and ocular presentation and treatment
Sr. no. | Age/sex | Fever | BCVA at presentation | BCVA at the final follow-up | Anterior segment | Posterior segment | Antibiotics | Steroids | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Skin rash | Joint pain | Ocular involvement | |||||||||||
OD | OS | OD | OS | ||||||||||
1 | F | 40 | 27 days | 20/60 | 20/40 | 20/20 | 20/20 | OU: quiet, AVF: cells+ | OU: MFR, M.S. | Doxy | Oral | ||
2 | M | 27 | 10 days | 20/2000 | 20/20 | 20/40 | 20/20 | OS: O.5 cells, AVF: cells+ | RE: MFR | Doxy | Oral + OD PST | ||
3 | M | 16 | √ | 10 days | 20/2000 | 20/80 | 20/60 | 20/30 | OU: quiet, AVF: cells+ | OU: MFR hemorrhages, M.E. | Nil | Oral | |
4 | F | 33 | 21 days | 20/2000 | 20/60 | 20/30 | 20/30 | OU: quiet, AVF: cells++ | OU: MFR, M.E. | Doxy | Oral + OS PST | ||
5 | F | 23 | 30 days | 20/125 | 20/2000 | 20/60 | 20/60 | OU: cells 1 +, AVF: Cells+ | OU: MFR, M.E. | Nil | Oral + OU PST | ||
6 | M | 29 | √ | √ | 15 days | 20/30 | 20/20 | Lost to follow-up | OD: quiet, AVF: cells+ | OD: focal retinitis | Doxy | Oral | |
7 | F | 16 | √ | √ | 28 days | 20/2000 | 20/800 | 20/30 | 20/30 | OU: N.G. KPs, cells+, AVF: cells++ | OU: MFR, M.E. | Doxy | IVMP + Oral |
8 | F | 34 | √ | 15 days | 20/30 | 20/20 | 20/20 | 20/20 | OU: quiet, AVF: cells+ | OU: MFR | Doxy | Oral + OS PST | |
9 | M | 64 | 27 days | 20/80 | 20/2000 | 20/30 | 20/40 | OU: N.G. KPs, cells+, AVF: cells+ | OU: MFR, M.E. | Doxy | Oral + OD PST | ||
10 | F | 22 | √ | 30 days | 20/6000 | 20/20 | Lost to follow-up | OU: cells+, AVF: cells+ | OU: MFR, OD: M.E., D.E. | Nil | Oral | ||